H.C. Wainwright raised the firm’s price target on Neurogene (NGNE) to $70 from $65 and keeps a Buy rating on the shares. The firm believes the new NGN-401 data “highlights an absurdly inverted valuation dynamic” between Taysha Gene Therapies (TSHA) and Neurogene. Taysha still trades at multiples of Neurogene’s valuation “despite the fact that NGN-401 has more advanced, durable, and clinically meaningful data,” the analyst tells investors in a research note. The firm says Taysha’s TSHA-102 still has no longitudinal patient-level detail and no evidence of accumulating multi-skill gains.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene’s NGN-401: Promising Phase I/II Results and Strategic Advancements Justify Buy Rating
- Neurogene Announces Positive Interim Data for NGN-401
- Neurogene reports interim data in Pediatric Cohort from NGN-401 trial
- Optimistic Buy Rating for Neurogene: Advancements in NGN-401 Therapy and Strategic Developments
- Neurogene Positioned for Market Leadership with Advancements in Rett Syndrome Gene Therapy